GE HealthCare's End-tidal Control Software Cuts Anesthetic Use by 39% in Large-Scale Study
Event summary
- Retrospective study of 12,818 cases at University of Michigan found GE HealthCare's End-tidal Control software used in 52.7% of procedures.
- Software associated with 62.3% reduction in median fresh gas flow and 39.3% reduction in sevoflurane consumption.
- Study conducted between April 2023 and September 2024, published October 16, 2026.
- Software designed to maintain target anesthetic agent and oxygen concentrations with greater accuracy than manual adjustments.
The big picture
The study validates GE HealthCare's End-tidal Control software as a tool for reducing anesthetic agent consumption and greenhouse gas emissions, aligning with broader healthcare industry trends toward sustainability and cost efficiency. The findings suggest potential for significant operational savings, particularly in large academic health systems where anesthesia delivery is high-volume. The software's integration with the Aisys™ CS2 anesthesia delivery system positions GE HealthCare to capture market share in the growing low-flow anesthesia segment.
What we're watching
- Adoption Dynamics
- How GE HealthCare will scale End-tidal Control adoption across diverse clinical settings.
- Cost Savings
- Whether the projected cost savings from reduced anesthetic use will drive broader healthcare system adoption.
- Regulatory Compliance
- The pace at which regulatory bodies may require or incentivize low-flow anesthesia technologies.